The acquisition of global rights to NJO from Sanofi is expected to contribute positively to EBITDA from 2025 onwards. Recordati SpA (RICFY) reported a robust free cash flow of 434.3 million euros, up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback